Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…
A constructive meeting between Biopharma and Site Head Stada Inna Udovenko took place on July 20, 2023. The goal was to discuss cooperation on testing Stada products, which will improve…